Docoh
Loading...

ALXN Alexion Pharmaceuticals

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

Company profile

Ticker
ALXN
Exchange
Website
CEO
Ludwig Hantson
Employees
Incorporated
Location
Fiscal year end
Former names
ALEXION PHARMACEUTICALS INC
SEC CIK
IRS number
133648318

ALXN stock data

(
)

Calendar

30 Apr 21
4 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
21 Jul 21 John J Orloff Common Stock, par value $.0001 per share Sale back to company Dispose D No No 0 146,511 0 0
21 Jul 21 Ludwig Hantson Common Stock, par value $.0001 per share Sale back to company Dispose D No No 0 580,809 0 9,098
21 Jul 21 Ludwig Hantson Option to Purchase Common Stock Common Stock, par value $.0001 per share Sale back to company Dispose D No No 118.83 56,762 6.75M 0
21 Jul 21 Rummelt Andreas Common Stock, par value $.0001 per share Sale back to company Dispose D No No 0 28,109 0 0
21 Jul 21 Rummelt Andreas Option to Purchase Common Stock Common Stock, par value $.0001 per share Sale back to company Dispose D No No 155.01 2,343 363.19K 0
21 Jul 21 Rummelt Andreas Option to Purchase Common Stock Common Stock, par value $.0001 per share Sale back to company Dispose D No No 85.75 3,237 277.57K 0
21 Jul 21 Rummelt Andreas Option to Purchase Common Stock Common Stock, par value $.0001 per share Sale back to company Dispose D No No 96.35 3,425 330K 0
21 Jul 21 Rummelt Andreas Option to Purchase Common Stock Common Stock, par value $.0001 per share Sale back to company Dispose D No No 138.86 2,294 318.54K 0
21 Jul 21 Rummelt Andreas Option to Purchase Common Stock Common Stock, par value $.0001 per share Sale back to company Dispose D No No 159.7 2,785 444.76K 0
21 Jul 21 Nader Francois Common Stock, par value $.0001 per share Sale back to company Dispose D No No 0 13,921 0 0

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

82.8% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 725 799 -9.3%
Opened positions 82 190 -56.8%
Closed positions 156 82 +90.2%
Increased positions 231 234 -1.3%
Reduced positions 307 279 +10.0%
13F shares
Current Prev Q Change
Total value 27.99B 30.12B -7.1%
Total shares 183.03M 192.79M -5.1%
Total puts 1.63M 2.44M -33.4%
Total calls 1.28M 2.66M -51.8%
Total put/call ratio 1.3 0.9 +38.2%
Largest owners
Shares Value Change
Vanguard 19.57M $2.99B +0.8%
BLK Blackrock 17.55M $2.68B -3.4%
STT State Street 9.88M $1.51B -7.1%
Pentwater Capital Management 4.29M $655.87M +44.9%
Adage Capital Partners GP, L.L.C. 4.24M $648.7M +45.4%
Baker Bros. Advisors 3.99M $610.62M -54.4%
Geode Capital Management 3.97M $605.51M +3.3%
BCS Barclays 3.58M $547.17M +877.3%
FMR 3.53M $539.48M -43.9%
Renaissance Technologies 3.33M $508.9M -19.1%
Largest transactions
Shares Bought/sold Change
Clearbridge Advisors 0 -5.87M EXIT
Baker Bros. Advisors 3.99M -4.77M -54.4%
BCS Barclays 3.58M +3.21M +877.3%
Norges Bank 0 -3.17M EXIT
FMR 3.53M -2.76M -43.9%
C Citigroup 3.28M +2.16M +192.4%
Swedbank 0 -2.14M EXIT
JHG Janus Henderson 642.82K -2.05M -76.2%
JPM JPMorgan Chase & Co. 2.26M -2.05M -47.5%
AMP Ameriprise Financial 415.76K -1.93M -82.3%

Financial report summary

?
Management Discussion
  • Item 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
  • This quarterly report on Form 10-Q contains forward-looking statements. Words such as “anticipates,” "may," "forecasts," “expects,” “intends,” “plans,” "potentially," “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict; therefore, actual results may differ materially from those expressed or forecasted in any such statements. Such forward-looking statements are based on current expectations, estimates and projections about our industry and business, management's beliefs, and certain assumptions made by our management, and may include, but are not limited to, statements regarding:
  • Alexion Pharmaceuticals, Inc.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: abetted, absorb, accuracy, acuity, albumin, alkaline, ALP, ameliorate, American, antagonist, appraisal, asfotase, assign, AstraZeneca, ATTRm, ATTRwt, automatic, automatically, ballot, beneficiary, Berger, Bidco, bioavailability, bispecific, bridge, CCPA, Certificate, certified, cGLP, chemical, choice, circular, circulating, congressional, context, CPRA, Del, Delta, depositary, depository, dermatology, devoted, digestive, dissemination, divest, divestiture, doctrine, document, duty, dyscrasia, dysfunction, endothelial, England, enjoining, eventually, expressly, fatal, fiduciary, flaccid, forum, fosdenopterin, glomerulonephropathy, Goldman, hereof, HREC, HSCT, HSR, ICs, IDMC, incentive, incident, injection, insult, issuable, IVH, Kent, Kr, lifelong, LLC, lowest, master, McKenzie, median, MFN, misfolded, mobilize, Morgan, motivate, motivating, Naquin, Nasdaq, neuropathy, noncontrolling, notably, NTproBNP, NULIBRY, nurse, officio, Omega, omitted, ordinary, Organisation, outflow, Pa, par, Parshall, pendency, peripheral, Phenotypically, phosphatase, plc, potent, Priority, prognostic, programmatic, promulgated, properdin, proxy, PRV, pulmonology, Raul, recourse, redirect, registration, relationship, relaunch, remeasurement, renegotiate, rescission, rescissory, Rhythm, satisfaction, segmented, septic, Shield, shock, SLE, speaker, Speed, Stanley, subcontract, tetraplegia, thereof, thereon, timeframe, tissue, transplant, Transplantation, troponin, unaffected, unanimously, unmet, unreasonably, unwind, VIE, visual, Votto, Voucher, waived, waiver, Wang, Warp, weekly, Wei, wild, withheld
Removed: AB, accident, Aid, AMT, analyzing, ARIMF, art, avoid, back, basket, begun, benchmark, bile, Biliary, bind, bivalent, capitalizing, carryback, CCA, China, circumstance, cloud, collectibility, combine, communicate, conform, conformity, deduct, deduction, delaying, disaggregate, distancing, EAP, educating, enactment, episode, excellence, Fast, France, hosting, hyaluronidase, improvement, inadvertently, indefinitely, inpatient, involuntarily, Island, isolation, jeopardizing, line, live, location, Moderna, morale, NOL, opened, originally, originated, paragraph, petitioned, pneumonia, pool, population, privately, PTO, qualifying, qualitative, quantitative, quarantine, realization, reallocation, reassessed, recoverable, recovering, redesign, regularly, repealed, requirement, reviewed, Rhode, safeguarding, sense, sentence, serum, software, stay, streamline, supportable, task, taxable, Track, transitioning, Trump, understanding, undertook, validate, visible